Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1992 Mar;87(3):504–508. doi: 10.1111/j.1365-2249.1992.tb03027.x

Vasoactive intestinal peptide stimulates immunoglobulin production and growth of human B cells.

C Ishioka 1, A Yoshida 1, H Kimata 1, H Mikawa 1
PMCID: PMC1554343  PMID: 1311995

Abstract

The effect of vasoactive intestinal peptide (VIP) on human lymphoblastoid B cell lines and tonsil B cells was studied. VIP increased immunoglobulin production and proliferation by lymphoblastoid B cell line, GM-1056, in a dose-dependent manner. As little as 10(-12) M of VIP was effective, and higher concentrations of VIP induced an approximately five-fold increase in IgA production. Moreover, this enhancement was blocked by VIP antagonist. Similarly, VIP enhanced IgM and IgG production by other lymphoblastoid B cell lines, CBL and IM-9, respectively. In contrast to VIP, another neuropeptide substance P (SP) or somatostatin failed to enhance immunoglobulin production and thymidine uptake. VIP also enhanced IgA production and thymidine uptake by purified tonsil B cells. However, in contrast to B cell lines, VIP failed to enhance IgM and IgG production by tonsil B cells. SP or somatostatin failed to enhance immunoglobulin production or thymidine uptake by tonsil B cells. These results indicate that VIP acts as B cell stimulatory factor and that VIP may also have preferential effect on IgA production on tonsil B cells.

Full text

PDF
507

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aliakbari J., Sreedharan S. P., Turck C. W., Goetzl E. J. Selective localization of vasoactive intestinal peptide and substance P in human eosinophils. Biochem Biophys Res Commun. 1987 Nov 13;148(3):1440–1445. doi: 10.1016/s0006-291x(87)80293-0. [DOI] [PubMed] [Google Scholar]
  2. Anderson K. C., Jones R. M., Morimoto C., Leavitt P., Barut B. A. Response patterns of purified myeloma cells to hematopoietic growth factors. Blood. 1989 May 15;73(7):1915–1924. [PubMed] [Google Scholar]
  3. Beed E. A., O'Dorisio M. S., O'Dorisio T. M., Gaginella T. S. Demonstration of a functional receptor for vasoactive intestinal polypeptide on Molt 4b T lymphoblasts. Regul Pept. 1983 Apr;6(1):1–12. doi: 10.1016/0167-0115(83)90129-5. [DOI] [PubMed] [Google Scholar]
  4. Binder H. J., Lemp G. F., Gardner J. D. Receptors for vasoactive intestinal peptide and secretin on small intestinal epithelial cells. Am J Physiol. 1980 Mar;238(3):G190–G196. doi: 10.1152/ajpgi.1980.238.3.G190. [DOI] [PubMed] [Google Scholar]
  5. Böyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl. 1968;97:77–89. [PubMed] [Google Scholar]
  6. Calvo J. R., Guerrero J. M., Molinero P., Blasco R., Goberna R. Interaction of vasoactive intestinal peptide (VIP) with human peripheral blood lymphocytes: specific binding and cyclic AMP production. Gen Pharmacol. 1986;17(2):185–189. doi: 10.1016/0306-3623(86)90137-0. [DOI] [PubMed] [Google Scholar]
  7. Carlquist M., Jörnvall H., Tatemoto K., Mutt V. A porcine brain polypeptide is identical to the vasoactive intestinal polypeptide. Gastroenterology. 1982 Jul;83(1 Pt 2):245–249. [PubMed] [Google Scholar]
  8. Desbuquois B. The interaction of vasoactive intestinal polypeptide and secretin with liver-cell membranes. Eur J Biochem. 1974 Aug 1;46(3):439–450. doi: 10.1111/j.1432-1033.1974.tb03637.x. [DOI] [PubMed] [Google Scholar]
  9. Dupont C., Laburthe M., Broyart J. P., Bataille D., Rosselin G. Cyclic AMP production in isolated colonic epithelial crypts: a highly sensitive model for the evaluation of vasoactive intestinal peptide action in human intestine. Eur J Clin Invest. 1980 Feb;10(1):67–76. doi: 10.1111/j.1365-2362.1980.tb00012.x. [DOI] [PubMed] [Google Scholar]
  10. Finch R. J., Sreedharan S. P., Goetzl E. J. High-affinity receptors for vasoactive intestinal peptide on human myeloma cells. J Immunol. 1989 Mar 15;142(6):1977–1981. [PubMed] [Google Scholar]
  11. Guerrero J. M., Prieto J. C., Elorza F. L., Ramirez R., Goberna R. Interaction of vasoactive intestinal peptide with human blood mononuclear cells. Mol Cell Endocrinol. 1981 Feb;21(2):151–160. doi: 10.1016/0303-7207(81)90052-6. [DOI] [PubMed] [Google Scholar]
  12. Kimata H., Saxon A. Subset of natural killer cells is induced by immune complexes to display Fc receptors for IgE and IgA and demonstrates isotype regulatory function. J Clin Invest. 1988 Jul;82(1):160–167. doi: 10.1172/JCI113565. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kimata H., Sherr E. H., Saxon A. Human natural killer (NK) cells produce a late-acting B-cell differentiation activity. J Clin Immunol. 1988 Sep;8(5):381–389. doi: 10.1007/BF00917154. [DOI] [PubMed] [Google Scholar]
  14. Kimata H., Yoshida A., Ishioka C., Mikawa H. Nerve growth factor inhibits immunoglobulin production by but not proliferation of human plasma cell lines. Clin Immunol Immunopathol. 1991 Jul;60(1):145–151. doi: 10.1016/0090-1229(91)90120-y. [DOI] [PubMed] [Google Scholar]
  15. Kimata H., Yoshida A., Ishioka C., Mikawa H. Stimulation of Ig production and growth of human lymphoblastoid B-cell lines by nerve growth factor. Immunology. 1991 Mar;72(3):451–452. [PMC free article] [PubMed] [Google Scholar]
  16. Larsson L. I., Polak J. M., Buffa R., Sundler F., Solcia E. On the immunocytochemical localization of the vasoactive intestinal polypeptide. J Histochem Cytochem. 1979 May;27(5):936–938. doi: 10.1177/27.5.479555. [DOI] [PubMed] [Google Scholar]
  17. Lygren I., Revhaug A., Burhol P. G., Giercksky K. E., Jenssen T. G. Vasoactive intestinal polypeptide and somatostatin in leucocytes. Scand J Clin Lab Invest. 1984 Jun;44(4):347–351. doi: 10.3109/00365518409083818. [DOI] [PubMed] [Google Scholar]
  18. Nordlind K., Mutt V. Influence of beta-endorphin, somatostatin, substance P and vasoactive intestinal peptide on the proliferative response of human peripheral blood T lymphocytes to mercuric chloride. Int Arch Allergy Appl Immunol. 1986;80(3):326–328. doi: 10.1159/000234073. [DOI] [PubMed] [Google Scholar]
  19. O'Dorisio M. S., Hermina N. S., O'Dorisio T. M., Balcerzak S. P. Vasoactive intestinal polypeptide modulation of lymphocyte adenylate cyclase. J Immunol. 1981 Dec;127(6):2551–2554. [PubMed] [Google Scholar]
  20. O'Dorisio M. S., O'Dorisio T. M., Cataland S., Balcerzak S. P. Vasoactive intestinal polypeptide as a biochemical marker for polymorphonuclear leukocytes. J Lab Clin Med. 1980 Oct;96(4):666–672. [PubMed] [Google Scholar]
  21. O'Dorisio M. S., Shannon B. T., Fleshman D. J., Campolito L. B. Identification of high affinity receptors for vasoactive intestinal peptide on human lymphocytes of B cell lineage. J Immunol. 1989 May 15;142(10):3533–3536. [PubMed] [Google Scholar]
  22. Ottaway C. A., Bernaerts C., Chan B., Greenberg G. R. Specific binding of vasoactive intestinal peptide to human circulating mononuclear cells. Can J Physiol Pharmacol. 1983 Jul;61(7):664–671. doi: 10.1139/y83-103. [DOI] [PubMed] [Google Scholar]
  23. Ottaway C. A., Greenberg G. R. Interaction of vasoactive intestinal peptide with mouse lymphocytes: specific binding and the modulation of mitogen responses. J Immunol. 1984 Jan;132(1):417–423. [PubMed] [Google Scholar]
  24. Ottaway C. A., Lay T. E., Greenberg G. R. High affinity specific binding of vasoactive intestinal peptide to human circulating T cells, B cells and large granular lymphocytes. J Neuroimmunol. 1990 Sep-Oct;29(1-3):149–155. doi: 10.1016/0165-5728(90)90157-i. [DOI] [PubMed] [Google Scholar]
  25. Ottaway C. A. Selective effects of vasoactive intestinal peptide on the mitogenic response of murine T cells. Immunology. 1987 Oct;62(2):291–297. [PMC free article] [PubMed] [Google Scholar]
  26. Rambaldi A., Young D. C., Herrmann F., Cannistra S. A., Griffin J. D. Interferon-gamma induces expression of the interleukin 2 receptor gene in human monocytes. Eur J Immunol. 1987 Jan;17(1):153–156. doi: 10.1002/eji.1830170127. [DOI] [PubMed] [Google Scholar]
  27. Rola-Pleszczynski M., Bolduc D., St-Pierre S. The effects of vasoactive intestinal peptide on human natural killer cell function. J Immunol. 1985 Oct;135(4):2569–2573. [PubMed] [Google Scholar]
  28. Said S. I., Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science. 1970 Sep 18;169(3951):1217–1218. doi: 10.1126/science.169.3951.1217. [DOI] [PubMed] [Google Scholar]
  29. Said S. I. Vasoactive intestinal polypeptide (VIP): current status. Peptides. 1984 Mar-Apr;5(2):143–150. doi: 10.1016/0196-9781(84)90197-9. [DOI] [PubMed] [Google Scholar]
  30. Spangelo B. L., Isakson P. C., MacLeod R. M. Production of interleukin-6 by anterior pituitary cells is stimulated by increased intracellular adenosine 3',5'-monophosphate and vasoactive intestinal peptide. Endocrinology. 1990 Jul;127(1):403–409. doi: 10.1210/endo-127-1-403. [DOI] [PubMed] [Google Scholar]
  31. Stanisz A. M., Befus D., Bienenstock J. Differential effects of vasoactive intestinal peptide, substance P, and somatostatin on immunoglobulin synthesis and proliferations by lymphocytes from Peyer's patches, mesenteric lymph nodes, and spleen. J Immunol. 1986 Jan;136(1):152–156. [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES